InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update

InflaRx NV shares on Nasdaq eased around 5% to roughly USD 2.28 at the start of June, keeping the German-Dutch biotech in focus as investors look toward the company’s next quarterly earnings update and progress of its anti-inflammatory pipeline.

InflaRx NV shares on Nasdaq remained volatile at the start of June, with the stock quoted around USD 2.28 on 06/01/2026 after a prior close near USD 2.40, according to Investing.com data as of that date (IFRX, Nasdaq). The US-listed biotech, which is domiciled in the Netherlands and focuses on anti-inflammatory drug candidates, traded in an intraday range of roughly USD 2.26 to USD 2.43 on that session, underlining continued sensitivity to news flow and expectations around its development programs.

Based on recent market snapshots, InflaRx NV carries the ticker IFRX on the Nasdaq exchange in the United States, which is the primary trading venue used by international investors to access the stock. The stock’s price behavior in early June followed prior swings seen over recent months as the company advanced its clinical pipeline in inflammation-driven indications and worked to convert trial progress into a clearer commercial outlook. For retail investors tracking the move, the price level around the low single digits still reflects the typical risk profile for development-stage biotech names listed in New York.

In parallel to the US listing, InflaRx NV also changes hands on German trading venues such as Börse Stuttgart under local identifiers, providing a bridge for investors in Germany who prefer to trade in euros. According to MarketScreener, the share recently traded near 1.95 EUR on Börse Stuttgart, which is broadly in line with the Nasdaq dollar quotation once exchange rates are taken into account. This cross-listing dynamic allows European investors to react to US news flow during extended trading hours while still transacting through domestic brokerage platforms.

The closing price region of around USD 2.28 on Nasdaq as of 06/01/2026, with a prior-day close of about USD 2.40, sits well below levels some analysts have discussed over the past year for InflaRx NV. Consensus figures compiled by MarketBeat earlier in 2026 indicated an average twelve-month price target of USD 7.00, based on coverage from several Wall Street research houses that follow the name. While such targets are not a forecast in themselves, the numerical gap between the trading price and these prior expectations underscores how much of the company’s long-term value proposition is still seen as conditional on future clinical and regulatory milestones.

For US investors on Nasdaq, the daily price swings in IFRX continue to be triggered by a mix of broader biotech sector sentiment, shifting risk appetite in growth stocks, and any incremental news on InflaRx NV’s studies. The company’s lead focus on anti-inflammatory mechanisms tied to the complement system places it within a specialized niche of the biopharmaceutical universe, where valuation can pivot quickly on trial readouts, regulatory interactions, and partnering activity with larger pharmaceutical groups. As of the beginning of June, no fresh company press release or SEC filing had been published in the immediate days before the latest price move, suggesting that general sector factors and technical trading were likely contributors to the short-term action.

From a home-country perspective, InflaRx NV is headquartered in Jena, Germany, but incorporated in the Netherlands and listed primarily on the Nasdaq in the United States via its IFRX ticker. This structure is common among European biotech firms seeking deep pools of specialist healthcare investors and higher liquidity than might be available on smaller local exchanges. It also means that regulatory disclosures relevant to equity investors are typically filed through US channels, with company investor-relations material available in English via the group’s website.

Although the latest trading day did not coincide with a new quarterly earnings release or guidance update, the Nasdaq price around USD 2.28 still embeds market expectations for the next set of reported figures. Development-stage companies like InflaRx NV usually operate with limited revenue and negative net income while they invest heavily in research and clinical trials, so investors pay close attention to cash runway disclosures, R&D spending, and any commentary on the timing of key clinical milestones in upcoming reports. These considerations form the backdrop against which the early-June share price and volume data should be interpreted.

As InflaRx NV prepares for its next quarterly communication, the current market capitalization implied by the low single-digit share price informs how much additional external financing, if any, might be required to support the pipeline. Equity-sensitive events such as follow-on offerings or at-the-market programs can influence trading behavior once announced, making the relationship between earnings disclosures, cash usage, and capital-market strategy a central focus for both US and European holders of the stock.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: IFRX
• Sector/industry: Biopharmaceuticals / anti-inflammatory therapies
• Headquarters/country: Jena, Germany / Netherlands domicile
• Core markets: United States, Europe
• Key revenue drivers: Potential future sales from complement-system-targeting anti-inflammatory drug candidates and any related licensing or collaboration income
• Home exchange/listing venue: Nasdaq (IFRX)
• Trading currency: USD

InflaRx NV: core business model

InflaRx NV concentrates on discovering and clinically developing therapies that modulate the complement system in order to address severe inflammatory conditions, aiming to translate successful trial outcomes into future product approvals and commercial partnerships.

Latest quarterly results for InflaRx NV at a glance

For a development-stage biotech like InflaRx NV, quarterly results are typically dominated by research and development spend, general and administrative expenses, and detailed commentary on clinical timelines rather than by large revenue contributions. In its most recent reported quarter prior to early June 2026, the company continued to emphasize investment into its pipeline of complement-targeting drug candidates, reflecting the capital-intensive nature of late-stage clinical work and regulatory preparation.

While headline figures such as net loss and earnings per share remain negative, as is customary for companies in this part of the biopharma life cycle, the earnings releases provide visibility on the length of the cash runway and management’s assumptions on how far existing resources can fund operations. Investors monitoring IFRX on Nasdaq focus on these disclosures to assess dilution risk and to gauge whether potential value-creating events like trial readouts or regulatory submissions can be reached before additional funding needs to be raised. The precise dates and amounts reported in those quarterly statements form a critical input into how the equity market prices the stock at levels like the roughly USD 2.28 seen on 06/01/2026.

Conclusion

The early-June trading pattern in InflaRx NV, with the stock around USD 2.28 on Nasdaq and a parallel quotation close to 1.95 EUR in Germany, highlights how market participants continue to weigh development and financing risks against the potential rewards of the company’s complement-system approach. The most recent quarterly figures, though still loss-making, provide essential context on cash usage and the expected runway to upcoming clinical catalysts, which will likely be central in shaping the next phase of price discovery. For now, IFRX remains a development-driven biotech story where investor attention is firmly fixed on the intersection of trial progress, balance-sheet strength, and timing of the next scheduled earnings update.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.